Navigation Links
Ashkenazi ovarian cancer patients with BRCA mutations live longer than those with normal gene
Date:1/1/2008

Alexandria, VAIsraeli investigators have found that Ashkenazi Jewish women with ovarian cancer who have mutations in the BRCA1 or BRCA2 genes lived significantly longer than Ashkenazi Jewish ovarian cancer patients without these mutations. After up to nine years of follow-up, BRCA1/2 mutation carriers were 28 percent less likely to die from the disease, even though women with the BRCA mutations are significantly more likely to develop ovarian and breast cancers. The study is being published January 1 in the Journal of Clinical Oncology (JCO).

These findings are encouraging news for BRCA mutation carriers, said Siegal Sadetzki, MD, MPH, head of the Cancer & Radiation Epidemiology Unit at the Gertner Institute, Chaim Sheba Medical Center in Tel Hashomer, Israel and the studys senior author. Its possible that patients with these mutations respond better to chemotherapy hopefully, once we learn more about the mechanisms of this response, tailoring individual treatment will further improve survival.

Normal BRCA1/2 genes control cell growth. Mutations in these genes, which are more common among Ashkenazi Jewish women (Jewish women of Eastern European descent) than in the general population, increase the risk of breast and ovarian cancers.

In one of the largest studies of this topic to date, the researchers from the National Israeli Study of Ovarian Cancer compared five-year survival between 213 Ashkenazi ovarian cancer patients with BRCA1/2 mutations (carriers) and 392 Ashkenazi ovarian cancer patients without the mutations (non-carriers).

After five years, 46 percent of the carriers were still alive, compared with 34.4 percent of the non-carriers. Median survival was 53.7 months for carriers and 37.9 months for non-carriers. The differences in survival were most pronounced for women diagnosed with more advanced disease (stage III or IV), with five-year survival rates of 38.1 percent for carriers and 24.5 percent for non-carriers. These findings persisted after controlling for other factors that influence ovarian cancer survival, such as patient age and some biological features of the tumor.

The researchers also analyzed ovarian cancer survival according to whether women had a BRCA1 or a BRCA2 mutation. Women with BRCA1 mutations lived a median of 45.1 months, and women with BRCA2 mutations lived a median of 52.5 months.


'/>"/>

Contact: Tiffany Reynolds
reynoldt@asco.org
703-519-1423
American Society of Clinical Oncology
Source:Eurekalert

Related medicine news :

1. Cranberry Could Juice Up Ovarian Cancer Treatment
2. New Ovarian Cancer Drug Trial Under Way
3. Pelvic Exams Can Help Spot Ovarian Cancer
4. Study fuels debate over whether exercise and body size influence ovarian cancer risk
5. Experimental drug boosts survival in recurrent ovarian cancer
6. New Ovarian Cancer Biomarker Research Act Introduced
7. Common Early-Warning Symptoms of Ovarian Cancer Identified in CDC/Thomson Healthcare Study
8. More Fiber, Less Fat Help Prevent Ovarian Cancer
9. Media availability: low-fat dietary pattern may lower risk of ovarian cancer
10. The Silent Killer, Ovarian Cancer on Your Cancer Today (TM)
11. Society of Gynecologic Oncologists Provides Guidelines for Offering Genetic Risk Assessment to Women With a Personal or Family History of Breast, Ovarian, Uterine or Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/19/2017)... ... 2017 , ... Braun Industries will be participating as an exhibitor at EMS ... place February 23-25, 2017 at the Calvin L. Rampton Salt Palace Convention Center in ... new ambulances on display. , “JEMS is a leader in EMS news ...
(Date:2/18/2017)... Massachusetts (PRWEB) , ... February 17, 2017 , ... ... the leading source of disruptive innovation in the industry, according to the recent ... Reports are based on surveys of the NEJM Catalyst Insights Council, a qualified ...
(Date:2/18/2017)... ... February 18, 2017 , ... ... the latest information and contact points to easily connect elderly veterans of America's ... living, and elder-care funding. It also conveys material on this year's increase in ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... its educational assistance management solution to the exhibit floor for the 2017 ... Fla. , From Feb. 19–23, 2017, more than 40,000 healthcare industry professionals ...
(Date:2/17/2017)... ... February 17, 2017 , ... Access today ... Exhibition in Orlando, Fla., February 19-23. Visitors to the company’s booth (#1778) will ... used electronic patient signatures solution in healthcare . , Since it first ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... , Feb. 17, 2017  Perrigo Company plc (NYSE, TASE: PRGO) ... Food and Drug Administration for hydrocodone bitartrate and homatropine methylbromide ... Hydrocodone bitartrate and homatropine methylbromide oral solution (syrup), ... symptomatic relief of cough in adults and children 6 years ... ending January 2017 were approximately $16 million.   ...
(Date:2/17/2017)... 17, 2017 Research and Markets has announced the ... report to their offering. ... report provides separate comprehensive analytics for the US, Canada ... Asia-Pacific , Latin America , and Rest ... through 2022. Also, a six-year historic analysis is provided for these markets. ...
(Date:2/17/2017)... MIAMI , Feb. 17, 2017  In partnership ... Friends for Good Health , The Jack ... container filled with millions of dollars, worth of medicine ... Haiti . IHI is a non-profit dedicated to ... IHI is extremely active in Haiti ...
Breaking Medicine Technology: